-

04:09:21 PM

CLDX Stock News

CLDX - Celldex Therapeutics Inc.

06/21/22 8:00 AM

Nasdaq : CLDX

clinical trial

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humanized monoclonal antibody

RHEA-AI

neutral

06/16/22 4:01 PM

Nasdaq : CLDX

management

Celldex Announces Two New Appointments to its Board of Directors

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of Directors. “We are thrilled to welcome Cheryl and Garry to our Board of Directors during an important time

RHEA-AI

neutral

06/06/22 4:05 PM

Nasdaq : CLDX

conferences

Celldex to Present at the 2022 Jefferies Global Healthcare Conference

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET. A webcast of the

RHEA-AI

neutral

05/19/22 9:23 AM

Nasdaq : CLDX

clinical trial

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU), has been accepted as a late-breaking

RHEA-AI

neutral

05/05/22 4:01 PM

Nasdaq : CLDX

earnings

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “This quarter, we continued to focus on advancing our clinical programs and are on track to report

RHEA-AI

neutral

02/28/22 4:01 PM

Nasdaq : CLDX

earnings

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

CSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022 Expanded development of CDX-0159 into Eosinophilic Esophagitis (EoE) Well capitalized with $408.3 million in

RHEA-AI

neutral

02/22/22 4:01 PM

Nasdaq : CLDX

conferencesearnings

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highlights. To access

RHEA-AI

neutral

02/10/22 4:05 PM

Nasdaq : CLDX

conferences

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:00 p.m. ET. A webcast of

RHEA-AI

neutral

12/08/21 8:01 AM

Nasdaq : CLDX

clinical trial

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds the

RHEA-AI

neutral

11/12/21 7:00 AM

Nasdaq : CLDX

clinical trial

Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data

RHEA-AI

very positive

CLDX Data

Websitewww.celldex.com
CeoAnthony Marucci
Security nameCelldex Therapeutics Inc.
Issue typecs
Sic code2836
Employees124
Tags
- Health Technology
- Biotechnology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address53 Frontage Rd Ste 220
StateNew Jersey
CityHampton
Zip08827-4034
CountryUS
Phone19082007500

About Celldex Therapeutics Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.